Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1CheckMate 141, 20161KEYNOTE-040 (all population), 20181EAGLE (D vs ICC), 20191EAGLE (DT vs ICC), 2019durvalumab alone vs. durvalumab plus tremelimumab 0.85 [0.64; 1.12]0.85 [0.64;1.12]durvalumab alone vs. durvalumab plus tremelimumab 0.85 [0.64; 1.12]durvalumab alone vs. nivolumab alone 1.26 [0.86; 1.83]1.26 [0.86;1.83]durvalumab alone vs. nivolumab alone 1.26 [0.86; 1.83]durvalumab alone vs. pembrolizumab alone 1.10 [0.82; 1.47]1.10 [0.82;1.47]durvalumab alone vs. pembrolizumab alone 1.10 [0.82; 1.47]durvalumab alone vs. Standard of Care (SoC) 0.88 [0.72; 1.08]0.88 [0.72;1.08]durvalumab alone vs. Standard of Care (SoC) 0.88 [0.72; 1.08]durvalumab plus tremelimumab vs. durvalumab alone 1.18 [0.89; 1.57]1.18 [0.89;1.57]durvalumab plus tremelimumab vs. durvalumab alone 1.18 [0.89; 1.57]durvalumab plus tremelimumab vs. nivolumab alone nivolumab alone better 1.49 [1.02; 2.16]1.49 [1.02;2.16]durvalumab plus tremelimumab vs. nivolumab alone nivolumab alone better 1.49 [1.02; 2.16]durvalumab plus tremelimumab vs. pembrolizumab alone 1.30 [0.98; 1.73]1.30 [0.98;1.73]durvalumab plus tremelimumab vs. pembrolizumab alone 1.30 [0.98; 1.73]durvalumab plus tremelimumab vs. Standard of Care (SoC) 1.04 [0.85; 1.27]1.04 [0.85;1.27]durvalumab plus tremelimumab vs. Standard of Care (SoC) 1.04 [0.85; 1.27]nivolumab alone vs. durvalumab alone 0.80 [0.55; 1.16]0.80 [0.55;1.16]nivolumab alone vs. durvalumab alone 0.80 [0.55; 1.16]nivolumab alone vs. durvalumab plus tremelimumab nivolumab alone better 0.67 [0.46; 0.98]0.67 [0.46;0.98]nivolumab alone vs. durvalumab plus tremelimumab nivolumab alone better 0.67 [0.46; 0.98]nivolumab alone vs. pembrolizumab alone 0.87 [0.60; 1.28]0.87 [0.60;1.28]nivolumab alone vs. pembrolizumab alone 0.87 [0.60; 1.28]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.70 [0.51; 0.96]0.70 [0.51;0.96]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.70 [0.51; 0.96]pembrolizumab alone vs. durvalumab alone 0.91 [0.68; 1.21]0.91 [0.68;1.21]pembrolizumab alone vs. durvalumab alone 0.91 [0.68; 1.21]pembrolizumab alone vs. durvalumab plus tremelimumab 0.77 [0.58; 1.02]0.77 [0.58;1.02]pembrolizumab alone vs. durvalumab plus tremelimumab 0.77 [0.58; 1.02]pembrolizumab alone vs. nivolumab alone 1.14 [0.78; 1.67]1.14 [0.78;1.67]pembrolizumab alone vs. nivolumab alone 1.14 [0.78; 1.67]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.80 [0.65; 0.98]0.80 [0.65;0.98]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.80 [0.65; 0.98]Standard of Care (SoC) vs. durvalumab alone 1.14 [0.93; 1.39]1.14 [0.93;1.39]Standard of Care (SoC) vs. durvalumab alone 1.14 [0.93; 1.39]Standard of Care (SoC) vs. durvalumab plus tremelimumab 0.96 [0.79; 1.17]0.96 [0.79;1.17]Standard of Care (SoC) vs. durvalumab plus tremelimumab 0.96 [0.79; 1.17]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.43 [1.04; 1.96]1.43 [1.04;1.96]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.43 [1.04; 1.96]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.25 [1.02; 1.53]1.25 [1.02;1.53]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.25 [1.02; 1.53]Standard of Care (SoC)nivolumab alonepembrolizumab alonedurvalumab alonedurvalumab plus tremelimumabdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)nivolumab alonepembrolizumab alonedurvalumab alonedurvalumab plus tremelimumab
Standard of Care (SoC)---1.43
1.04; 1.96		1.25
1.02; 1.53		1.14
0.93; 1.39		0.96
0.79; 1.17
nivolumab alone0.70
0.51; 0.96		---0.87
0.60; 1.28		0.80
0.55; 1.16		0.67
0.46; 0.98
pembrolizumab alone0.80
0.65; 0.98		1.14
0.78; 1.67		---0.91
0.68; 1.21		0.77
0.58; 1.02
durvalumab alone0.88
0.72; 1.08		1.26
0.86; 1.83		1.10
0.82; 1.47		---0.85
0.64; 1.12
durvalumab plus tremelimumab1.04
0.85; 1.27		1.49
1.02; 2.16		1.30
0.98; 1.73		1.18
0.89; 1.57		---

pathologies: 101 - treatments: 634,861 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons